Arturo G. Porras - Concepedia

Author

Arturo G. Porras

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

A G Porras, A PORRAS, A Porras, A. G. PORRAS, A. G. Porras, A. PORRAS, A. Porras, A.G. Porras, Anna Pérez Porras, Arturo G Porras

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Clinical Research Associates KU Leuven Pharmaceutical Product Development (United States)

About

Arturo G. Porras is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.5K
2	Natural Sciences	3	3	360
3	Engineering	2	2	330
4	Health Sciences	2	2	37
5	Education	1	1	11

Arturo G. Porras

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects Cynthia Guzzo, Christine Furtek, Arturo G. Porras, The Journal of Clinical Pharmacology Drug SafetyTranslational MedicineAntiparasitic Drug IvermectinIvermectin Cns EffectsMedicine	2002	353
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model Elliot Ehrich, A. Dallob, I Delepeleire, Clinical Pharmacology & Therapeutics	1999	326
Substrate analog binding to the coupled binuclear copper active site in tyrosinase Dean E. Wilcox, Arturo G. Porras, Yeong Tsyr Hwang, Journal of the American Chemical Society EngineeringChemical AnalysisAltmetric Attention ScoreMolecular BiologyOrganic Chemistry	1985	309
Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects Cynthia Guzzo, Christine Furtek, Arturo G. Porras, The Journal of Clinical Pharmacology Drug SafetyTranslational MedicineAntiparasitic Drug IvermectinIvermectin Cns EffectsMedicine	2002	306
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis Sohail A. Khan, John А. Kanis, Samuel D Vasikaran, Journal of Bone and Mineral Research	1997	290
Studies of the oral bioavailability of alendronate* Barry J. Gertz, Sherry D. Holland, W. F. Kline, Clinical Pharmacology & Therapeutics Oral BioavailabilityGastric PhMetabolic Bone DiseaseMedicineClinical Nutrition	1995	258
Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study Julio Bobes, M. P. GARC A-PORTILLA, Javier Rejas, Journal of Sex & Marital Therapy	2003	213
Clinical pharmacology of alendronate sodium B. J. Gertz, Sherry D. Holland, W. F. Kline, Osteoporosis International MedicineClinical PharmacologyPharmacotherapyPharmacologyOsteoporosis	1993	160
The reaction of reduced xanthine oxidase with oxygen. Kinetics of peroxide and superoxide formation. Arturo G. Porras, John S. Olson, G Palmer Journal of Biological Chemistry Redox SignalingTrapping AgentBiochemistryHeme DegradationReduced Xanthine Oxidase	1981	134
Ligand binding to heme proteins. An evaluation of distal effects. Martha P. Mims, Arturo G. Porras, John S. Olson, Journal of Biological Chemistry	1983	124

Page 1